ZEN-2759

CAS No. 1616400-50-0

ZEN-2759( —— )

Catalog No. M36339 CAS No. 1616400-50-0

ZEN-2759 is a potent BET small molecule inhibitor of BRD4 (BD1), BRD4 (BD2), and BRD4 (BD1BD2).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 84 In Stock
5MG 123 In Stock
10MG 187 In Stock
25MG 305 In Stock
50MG 456 In Stock
100MG 624 In Stock
500MG 1305 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ZEN-2759
  • Note
    Research use only, not for human use.
  • Brief Description
    ZEN-2759 is a potent BET small molecule inhibitor of BRD4 (BD1), BRD4 (BD2), and BRD4 (BD1BD2).
  • Description
    ZEN-2759 is a potent BET (Bromodomain and Extra-Terminal Domain) inhibitor, with IC50 values of 0.23, 0.08 and 0.28 μM for BRD4(BD1), BRD4(BD2), and BRD4(BD1BD2), respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1616400-50-0
  • Formula Weight
    280.32
  • Molecular Formula
    C17H16N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (356.74 mM; Ultrasonic )
  • SMILES
    CC=1C(C2=CN(CC3=CC=CC=C3)C(=O)C=C2)=C(C)ON1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kharenko OA, et al. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine. J Med Chem. 2018 Sep 27;61(18):8202-8211. ?
molnova catalog
related products
  • BRM/BRG1 ATP Inhibit...

    BRM/BRG1 ATP Inhibitor-2 is an inhibitor of BRG1/BRM ATPase and can be used in studies about the treatment of BAF-related disorders.

  • OXFBD04

    OXFBD04 is a potent and selective inhibitor of BRD4(IC50 of 166 nM).

  • dCBP-1

    dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.